03 OCT 2008 05:51                LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                 
                                                                                                                        
                                                                 REGS.    REGS.    REGS.   REGS.  REGS.   # of    # of  
                                                ACCR.  TOTAL      LAST     LAST     LAST    LAST   LAST ACTIVE CURRENT  
STUDY    REG. ARM                                GOAL  REGS. 12 Months 6 Months 3 Months 30 DAYS 7 DAYS  INSTs    IRBs  
-------- ---- -------------------------------- ------ ------ --------- -------- -------- ------- ------ ------ -------  
S9007    1    1 cytogenetics sample                     3070       227      109       57      25      5    303     119  
                                                      ------ --------- -------- -------- ------- ------                 
                                                        3070       227      109       57      25      5                 
                                                                                                                        
                                                                                                                        
S9910    1    1 Specimen submission                     1024       221      105       55      23      4    267     106  
                                                      ------ --------- -------- -------- ------- ------                 
                                                        1024       221      105       55      23      4                 
                                                                                                                        
                                                                                                                        
S0106    1    1 ARA-C + Daunomycin + Mylotarg     684    222        87       52       28       9      2    206      87  
              2 ARA-C + Daunomycin                       230        93       52       32      12      1                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                         452       180      104       60      21      3                 
                                                                                                                        
         2    3 ARA-C Consolidation                      270       101       53       30      15      5    206      87  
                                                      ------ --------- -------- -------- ------- ------                 
                                                         270       101       53       30      15      5                 
                                                                                                                        
         3    4 Mylotarg                          342     66        26       13        8       4      0    206      87  
              5 Observation                               68        26       12        6       2      1                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                         134        52       25       14       6      1                 
                                                                                                                        
                                                                                                                        
S0325    1    1 Imatinib 400 mg/day               400    174        73       28       14       6      0    129      64  
              2 Imatinib 800 mg/day                       78         0        0        0       0      0                 
              3 Dasatinib                                101        63       31       15       7      2                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                         353       136       59       29      13      2                 
                                                                                                                        
                                                                                                                        
S0333    1    1 DNR + VCR + Pred + PEG-L-Asp       78     71        25       13        5       1      0    110      31  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          71        25       13        5       1      0                 
                                                                                                                        
         2    2 HD ARA-C + Mitoxantrone + GCSF            51        18        9        6       1      0    110      31  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          51        18        9        6       1      0                 
                                                                                                                        
         3    3 CTX + ARA-C + 6-MP + MTX +GCSF            35        16        8        5       3      0    110      31  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          35        16        8        5       3      0                 
                                                                                                                        
         4    4 Maintenance                               14         4        1        1       0      0    110      31  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          14         4        1        1       0      0                 
                                                                                                                        
                                                                                                                        
S0432    1    1 R115777 600mg BID x 21d q28d      296     83         0        0        0       0      0                 
              2 R115777 600mg BID x 7d q14d               90         0        0        0       0      0                 
              3 R115777 300mg BID x 21d q28d              86         0        0        0       0      0                 
              4 R115777 300mg BID x 7d q14d               89         0        0        0       0      0                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                         348         0        0        0       0      0                 
                                                                                                                        
         2    5 R115777 600mg BID x 21d q28d               7         1        0        0       0      0                 
              6 R115777 600mg BID x 7d q14d                2         0        0        0       0      0                 
              7 R115777 300mg BID x 21d q28d               7         1        0        0       0      0                 
              8 R115777 300mg BID x 7d q14d                2         0        0        0       0      0                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                          18         2        0        0       0      0                 
                                                                                                                        
                                                                                                                        
S0521    1    1 ATRA + ARA-C + Daunorubicin       500     18        18       11        3       1      1     96      40  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          18        18       11        3       1      1                 
                                                                                                                        
         2    2 Consolidation                             14        14        9        5       2      0     96      40  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          14        14        9        5       2      0                 
                                                                                                                        
                                                            

                                                                                                                   
03 OCT 2008 05:51                LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES                                 
                                                                                                                        
                                                                 REGS.    REGS.    REGS.   REGS.  REGS.   # of    # of  
                                                ACCR.  TOTAL      LAST     LAST     LAST    LAST   LAST ACTIVE CURRENT  
STUDY    REG. ARM                                GOAL  REGS. 12 Months 6 Months 3 Months 30 DAYS 7 DAYS  INSTs    IRBs  
-------- ---- -------------------------------- ------ ------ --------- -------- -------- ------- ------ ------ -------  
S0521    3    3 ATRA + 6MP + MTX                  400      1         1        1        1       0      0     96      40  
              4 Observation                                3         3        3        3       0      0                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                           4         4        4        4       0      0                 
                                                                                                                        
                                                                                                                        
S0530    1    1 Cytarabine + Clofarabine           35     37        31       10        1       0      0    104      30  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          37        31       10        1       0      0                 
                                                                                                                        
         2    2 Consolidation                              1         1        1        0       0      0    104      30  
                                                      ------ --------- -------- -------- ------- ------                 
                                                           1         1        1        0       0      0                 
                                                                                                                        
                                                                                                                        
S0605    1    1 Revlimid                           40     27        16        5        2       0      0     57      22  
                                                      ------ --------- -------- -------- ------- ------                 
                                                          27        16        5        2       0      0                 
                                                                                                                        
         2    2 Maintenance Revlimid                       9         7        2        1       0      0     57      22  
                                                      ------ --------- -------- -------- ------- ------                 
                                                           9         7        2        1       0      0                 
                                                                                                                        
                                                                                                                        
C10403   1    1 Sequential Chemotherapy           300      1         1        1        1       1      1     68      24  
                                                      ------ --------- -------- -------- ------- ------                 
                                                           1         1        1        1       1      1                 
                                                                                                                        
                                                                                                                        
E1905    1    1 Azacitidine                       123      6         0        0        0       0      0    120      55  
              2 Azacitidine + MS-275                      11         3        3        3       3      0                 
                                                      ------ --------- -------- -------- ------- ------                 
                                                          17         3        3        3       3      0                 
                                                                                                                        
                                                                                                                        





































                                                            

33 rows selected.

03 OCT 2008 05:51                        LEUK Open Studies with No Registrations                                        
                                                                                                                        
Study                                    Registration/Phase                  Open Date                                  
---------------------------------------- ----------------------------------- ---------                                  
S0521 APL,Low/Int Risk, Maint vs Obs     4 Post Consolidation Gemtuzumab     01jun2007                                  
S0535 APL,High Risk, ATRA/arsenic/GO     1 Induction                         15nov2007                                  
                                         2 Consolidation                     15nov2007                                  
                                         3 Maintenance                       15nov2007                                  
C10501 CLL, Early Intervention vs Obs    1 Endorsed Study                    22jan2008                                  














                                                            

5 rows selected.


no rows selected

SWOG StatCtr Home Page 1 row selected.